Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin, the active ingredient in Oncotice, is a live bacterial immunotherapy presented as a lyophilized powder for intravesical use. It is employed to treat non‑muscle invasive bladder cancer in adult patients, helping to reduce tumour recurrence after transurethral resection.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Oncotice is a live bacterial immunotherapy used in the management of bladder cancer and related urothelial conditions. - Non‑muscle invasive bladder cancer (NMIBC): reduces recurrence and progression after transurethral resection. - Carcinoma in situ of the bladder: induces a local immune response to eradicate tumour cells. - High‑risk recurrent NMIBC: provides adjunctive therapy to improve disease‑free survival.

Oncotice may cause a range of adverse reactions, most of which are local to the bladder, while rare systemic events can be serious.

Common Side Effects: - Cystitis‑like symptoms: urgency, frequency, dysuria. - Hematuria: visible blood in urine. - Low‑grade fever and chills. - Fatigue or malaise. - Mild abdominal discomfort. - Transient urinary incontinence.

Serious or Rare Side Effects: - Systemic BCG infection or sepsis. - Disseminated mycobacterial disease. - Severe allergic or anaphylactic reaction. - Granulomatous prostatitis. - Bladder contracture or fibrosis. - Persistent high‑grade fever with organ involvement.

Prior to initiating Oncotice therapy, clinicians should evaluate patient suitability and monitor for complications. - Active urinary infection: treat and resolve before BCG instillation. - Immunosuppression: avoid in patients receiving systemic steroids, chemotherapy or biologics. - Bladder integrity: contraindicated in cases of traumatic catheterisation or recent bladder surgery. - Pregnancy and breastfeeding: not recommended due to unknown fetal risk. - Monitoring: observe for systemic symptoms such as fever, weight loss or respiratory signs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

BCG interacts with several drug classes that modulate immune function or affect bladder healing.

Major Interactions (Avoid): - Systemic corticosteroids or high‑dose steroids. - Immunosuppressive biologics (e.g., anti‑TNF agents). - Cytotoxic chemotherapy administered concurrently. - Live vaccines given within 4 weeks of BCG. - Severe renal impairment requiring dialysis.

Moderate Interactions (Monitor Closely): - Intravesical chemotherapy agents given sequentially. - Anticoagulants: increased risk of hematuria. - NSAIDs used for fever control: may mask infection signs. - Antifungal agents that alter immune response. - Proton‑pump inhibitors: potential effect on bladder mucosa.